Cartherics is pleased to announce that Dr Madeline Cao, Research Fellow, will be presenting at Australia Biologics 2023 at Crown Promenade, Melbourne.
The Australia Biologics Festival 2023 is Australia’s premier conference that aims to gather the innovators, pioneers, leaders in the biologics fraternity including biologics, biosimilars, vaccines, cell and gene therapy (CGT) and evolving therapeutics […]
Melbourne, Victoria, Australia 27 February 2023
Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer.
The clinical trial to be conducted by Peter Mac will be the first […]
Cartherics is delighted to be hosting a Teal Tea this February to raise awareness and funds for people affected by ovarian cancer.
Ovarian Cancer Australia’s Teal Ribbon Day is an initiative that aims to start conversations that change lives. It will increase awareness of the disease and help raise funds to support people affected by […]
Cartherics is delighted to announce that Saleh Almasabi has successfully completed his PhD Candidature.
Saleh’s research thesis, ‘The role of integrin linked kinase in senescence and immunosuppressive tumor microenvironment in colon cancer’, identified that integrin-linked kinase (ILK) is associated with cancer prognosis and characterises the immunosuppressive tumor microenvironment. These findings suggest possible clinical avenues of targeting […]
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours.
Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ovarian, […]
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent filing WO2017088012.
The […]
Cartherics to Present at Biotech Showcase™ 2023
Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program at Biotech Showcase, with a view to engaging with potential investors and partners
Melbourne, Australia, 22 December 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it […]
This year has been an exciting and productive one for Cartherics. We opened our new and impressive research and development facility in Notting Hill and are busy completing the preclinical studies for our lead iNK product for treating ovarian cancer. The follow-on product pipeline is revving up with new CAR target candidates, additional gene edits […]
Ian Nisbet and Alan Trounson, AO
Australia is a very challenging environment for early-stage biotechnology companies. Risk capital is hard to find, and investors are wary of over-promising and under-delivering start-ups, that commonly go aground because of limited resources pitched against the costly demands and long timeframes of drug development.
For public companies, there is often a […]
Melbourne, Victoria, Australia – 08 November 2022
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).
“Patients with advanced stages of cutaneous T-cell lymphomas often […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
